Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Bluebird Bio, Inc. (BLUE)
since 2013 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Bluebird Bio, Inc..
Table 2 shows the detailed insider transactions.
This company's CIK number is 1293971.
Total stock buying since 2013: $900,936.
Total stock sales since 2013: $302,744,213.
Total stock option exercises since 2013: $18,164,530.
Table 3. Detailed insider trading at Bluebird Bio, Inc. (BLUE)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2025-03-03 | Colvin Richard A (Chief Medical Officer) | Sale | 584 | 3.92 | 2,288 |
| 2025-03-03 | Obenshain Andrew (President and CEO) | Sale | 921 | 3.92 | 3,609 |
| 2025-03-03 | Klima Thomas J (See Remarks) | Sale | 500 | 3.92 | 1,959 |
| 2025-02-03 | Colvin Richard A (Chief Medical Officer) | Sale | 64 | 7.39 | 473 |
| 2025-02-03 | Obenshain Andrew (President and CEO) | Sale | 86 | 7.39 | 635 |
| 2025-02-03 | Klima Thomas J (See Remarks) | Sale | 122 | 7.39 | 901 |
| 2025-02-03 | Vittiglio Joseph (Chief Business & Legal Officer) | Sale | 238 | 7.39 | 1,759 |
| 2025-01-06 | Colvin Richard A (Chief Medical Officer) | Sale | 19 | 9.24 | 175 |
| 2025-01-06 | Obenshain Andrew (President and CEO) | Sale | 140 | 9.24 | 1,293 |
| 2024-12-10 | Colvin Richard A (Chief Medical Officer) | Sale | 2,824 | .42 | 1,177 |
| 2024-12-10 | Obenshain Andrew (President and CEO) | Sale | 971 | .42 | 404 |
| 2024-09-30 | Obenshain Andrew (President and CEO) | Sale | 34,780 | .53 | 18,259 |
| 2024-09-30 | Klima Thomas J (See Remarks) | Sale | 1,006 | .53 | 529 |
| 2024-06-03 | Klima Thomas J (See Remarks) | Sale | 3,834 | .97 | 3,726 |
| 2024-02-05 | Obenshain Andrew (President and CEO) | Sale | 1,879 | .90 | 1,696 |
| 2024-02-05 | Klima Thomas J (See Remarks) | Sale | 2,714 | .90 | 2,450 |
| 2024-02-05 | Vittiglio Joseph (Chief Business & Legal Officer) | Sale | 5,217 | .90 | 4,710 |
| 2023-12-06 | Krawtschuk Christopher (Chief Financial Officer) | Sale | 4,526 | 4.52 | 20,439 |
| 2023-11-03 | Obenshain Andrew (President and CEO) | Sale | 807 | 3.17 | 2,554 |
| 2023-11-02 | Colvin Richard A (Chief Medical Officer) | Sale | 2,343 | 2.98 | 6,975 |
| 2023-09-05 | Klima Thomas J (See Remarks) | Sale | 922 | 3.79 | 3,493 |
| 2023-08-10 | Obenshain Andrew (President and CEO) | Sale | 16,929 | 3.54 | 59,962 |
| 2023-06-02 | Klima Thomas J (See Remarks) | Sale | 4,130 | 3.50 | 14,450 |
| 2022-11-04 | Colvin Richard A (Chief Medical Officer) | Sale | 218 | 6.41 | 1,398 |
| 2022-11-04 | Obenshain Andrew (President and CEO) | Sale | 1,263 | 6.41 | 8,100 |
| 2022-10-17 | Leiderman Elisabeth | Sale | 1,004 | 6.46 | 6,489 |
| 2022-08-04 | Obenshain Andrew (President and CEO) | Sale | 21,805 | 4.39 | 95,745 |
| 2022-08-04 | Cole Jason (Chief Strategy & Financial Officer) | Sale | 7,448 | 4.39 | 32,704 |
| 2022-07-12 | Eggimann Anne-virginie (Chief Regulatory Officer) | Sale | 1,358 | 4.95 | 6,722 |
| 2022-06-03 | Klima Thomas J (Chief Commercial Officer) | Sale | 3,753 | 3.07 | 11,536 |
| 2022-01-11 | Whitten Jessica (Chief Accounting Officer) | Sale | 279 | 9.64 | 2,690 |
| 2022-01-11 | Obenshain Andrew (President and CEO) | Sale | 4,683 | 9.64 | 45,158 |
| 2022-01-11 | Leschly Nick | Sale | 5,068 | 9.64 | 48,870 |
| 2022-01-11 | Cole Jason (Chief Operating and) | Sale | 3,387 | 9.64 | 32,660 |
| 2022-01-10 | Whitten Jessica (Chief Accounting Officer) | Sale | 130 | 9.40 | 1,222 |
| 2022-01-10 | Obenshain Andrew (President and CEO) | Sale | 3,042 | 9.32 | 28,360 |
| 2022-01-10 | Leschly Nick | Sale | 2,369 | 9.40 | 22,273 |
| 2022-01-10 | Cole Jason (Chief Operating and) | Sale | 1,584 | 9.40 | 14,892 |
| 2022-01-05 | Whitten Jessica (Chief Accounting Officer) | Sale | 2,984 | 10.44 | 31,144 |
| 2021-12-07 | Obenshain Andrew (President and CEO) | Sale | 832 | 10.18 | 8,468 |
| 2021-06-04 | Obenshain Andrew (President of SGD) | Sale | 511 | 30.75 | 15,715 |
| 2021-05-03 | Obenshain Andrew (President of SGD) | Sale | 29 | 30.15 | 874 |
| 2021-05-03 | Leschly Nick (President and CEO) | Sale | 444 | 30.15 | 13,387 |
| 2021-05-03 | Cole Jason (Chief Operating and) | Sale | 38 | 30.15 | 1,145 |
| 2021-05-03 | Gregory Philip D (Chief Scientific Officer) | Sale | 39 | 30.15 | 1,175 |
| 2021-04-05 | Obenshain Andrew (President of SGD) | Sale | 29 | 30.20 | 875 |
| 2021-04-05 | Davidson David (Chief Medical Officer) | Sale | 42 | 30.20 | 1,268 |
| 2021-04-05 | Leschly Nick (President and CEO) | Sale | 444 | 30.20 | 13,411 |
| 2021-04-05 | Cole Jason (Chief Operating and) | Sale | 37 | 30.20 | 1,117 |
| 2021-04-05 | Gregory Philip D (Chief Scientific Officer) | Sale | 39 | 30.20 | 1,177 |
| 2021-03-04 | Leschly Nick (President and CEO) | Option Ex | 203,355 | 5.50 | 1,118,452 |
| 2021-03-02 | Obenshain Andrew (President of SGD) | Sale | 34 | 29.58 | 1,005 |
| 2021-03-02 | Davidson David (Chief Medical Officer) | Sale | 42 | 29.58 | 1,242 |
| 2021-03-02 | Leschly Nick (President and CEO) | Sale | 444 | 29.58 | 13,134 |
| 2021-03-02 | Cole Jason (Chief Operating and) | Sale | 38 | 29.58 | 1,124 |
| 2021-03-02 | Gregory Philip D (Chief Scientific Officer) | Sale | 39 | 29.58 | 1,153 |
| 2021-02-17 | Obenshain Andrew (President of SGD) | Sale | 749 | 28.16 | 21,092 |
| 2021-02-17 | Burnett Katy (Principal Accounting Officer) | Sale | 518 | 28.16 | 14,587 |
| 2021-02-17 | Davidson David (Chief Medical Officer) | Sale | 698 | 28.16 | 19,656 |
| 2021-02-17 | Baird William D Iii (Chief Financial Officer) | Sale | 693 | 28.16 | 19,515 |
| 2021-02-17 | Cole Jason (Chief Operating and) | Sale | 665 | 28.16 | 18,727 |
| 2021-02-17 | Gregory Philip D (Chief Scientific Officer) | Sale | 664 | 28.16 | 18,698 |
| 2021-02-12 | Baird William D Iii (Chief Financial Officer) | Sale | 1,216 | 45.52 | 55,352 |
| 2021-02-02 | Obenshain Andrew (President of SGD) | Sale | 34 | 45.92 | 1,561 |
| 2021-02-02 | Davidson David (Chief Medical Officer) | Sale | 63 | 45.92 | 2,893 |
| 2021-02-02 | Leschly Nick (President and CEO) | Sale | 594 | 45.92 | 27,279 |
| 2021-02-02 | Cole Jason (Chief Operating and) | Sale | 38 | 45.92 | 1,745 |
| 2021-02-02 | Gregory Philip D (Chief Scientific Officer) | Sale | 59 | 45.92 | 2,709 |
| 2021-01-06 | Finger Alison Cecily (Chief Commercial Officer) | Sale | 1,814 | 45.11 | 81,831 |
| 2021-01-06 | Davidson David (Chief Medical Officer) | Sale | 3,167 | 45.11 | 142,866 |
| 2021-01-06 | Leschly Nick (President and CEO) | Sale | 10,095 | 45.11 | 455,395 |
| 2021-01-06 | Baird William D Iii (Chief Financial Officer) | Sale | 949 | 45.11 | 42,810 |
| 2021-01-06 | Cole Jason (Chief Operating and) | Sale | 2,358 | 45.11 | 106,371 |
| 2021-01-06 | Gregory Philip D (Chief Scientific Officer) | Sale | 2,754 | 45.11 | 124,235 |
| 2021-01-06 | Smith-farrell Joanne (COO, Oncology) | Sale | 1,287 | 45.11 | 58,057 |
| 2021-01-05 | Finger Alison Cecily (Chief Commercial Officer) | Sale | 40 | 44.95 | 1,798 |
| 2021-01-05 | Davidson David (Chief Medical Officer) | Sale | 48 | 44.95 | 2,157 |
| 2021-01-05 | Leschly Nick (President and CEO) | Sale | 333 | 44.95 | 14,969 |
| 2021-01-05 | Cole Jason (Chief Operating and) | Sale | 43 | 44.95 | 1,932 |
| 2021-01-05 | Gregory Philip D (Chief Scientific Officer) | Sale | 45 | 44.95 | 2,022 |
| 2021-01-05 | Smith-farrell Joanne (COO, Oncology) | Sale | 42 | 44.95 | 1,887 |
| 2020-12-03 | Burnett Katy (Principal Accounting Officer) | Sale | 123 | 46.09 | 5,668 |
| 2020-12-02 | Finger Alison Cecily (Chief Commercial Officer) | Sale | 36 | 46.34 | 1,668 |
| 2020-12-02 | Davidson David (Chief Medical Officer) | Sale | 64 | 46.34 | 2,966 |
| 2020-12-02 | Leschly Nick (President and CEO) | Sale | 444 | 46.34 | 20,577 |
| 2020-12-02 | Cole Jason (Chief Operating and) | Sale | 38 | 46.34 | 1,761 |
| 2020-12-02 | Gregory Philip D (Chief Scientific Officer) | Sale | 59 | 46.34 | 2,734 |
| 2020-12-02 | Smith-farrell Joanne (COO, Oncology) | Sale | 38 | 46.34 | 1,761 |
| 2020-11-02 | Finger Alison Cecily (Chief Commercial Officer) | Sale | 35 | 53.59 | 1,875 |
| 2020-11-02 | Davidson David (Chief Medical Officer) | Sale | 63 | 53.59 | 3,376 |
| 2020-11-02 | Leschly Nick (President and CEO) | Sale | 444 | 53.59 | 23,793 |
| 2020-11-02 | Cole Jason (Chief Operating and) | Sale | 37 | 53.59 | 1,982 |
| 2020-11-02 | Gregory Philip D (Chief Scientific Officer) | Sale | 59 | 53.59 | 3,161 |
| 2020-11-02 | Smith-farrell Joanne (COO, Oncology) | Sale | 37 | 53.59 | 1,982 |
| 2020-10-02 | Finger Alison Cecily (Chief Commercial Officer) | Sale | 36 | 52.77 | 1,899 |
| 2020-10-02 | Davidson David (Chief Medical Officer) | Sale | 64 | 52.77 | 3,376 |
| 2020-10-02 | Leschly Nick (President and CEO) | Sale | 450 | 52.77 | 23,744 |
| 2020-10-02 | Cole Jason (Chief Operating and) | Sale | 38 | 52.77 | 2,005 |
| 2020-10-02 | Gregory Philip D (Chief Scientific Officer) | Sale | 60 | 52.77 | 3,165 |
| 2020-10-02 | Smith-farrell Joanne (Chief Business Officer) | Sale | 38 | 52.77 | 2,005 |
| 2020-09-03 | Finger Alison Cecily (Chief Commercial Officer) | Sale | 35 | 58.60 | 2,051 |
| 2020-09-03 | Davidson David (Chief Medical Officer) | Sale | 41 | 58.60 | 2,402 |
| 2020-09-03 | Leschly Nick (President and CEO) | Sale | 431 | 58.60 | 25,257 |
| 2020-09-03 | Cole Jason (Chief Operating and) | Sale | 36 | 58.60 | 2,109 |
| 2020-09-03 | Gregory Philip D (Chief Scientific Officer) | Sale | 58 | 58.60 | 3,398 |
| 2020-09-03 | Smith-farrell Joanne (Chief Business Officer) | Sale | 36 | 58.60 | 2,109 |
| 2020-08-03 | Finger Alison Cecily (Chief Commercial Officer) | Sale | 35 | 60.65 | 2,122 |
| 2020-08-03 | Wentworth Kory James (Principal Accounting Officer) | Sale | 82 | 61.00 | 5,002 |
| 2020-08-03 | Davidson David (Chief Medical Officer) | Sale | 42 | 61.15 | 2,568 |
| 2020-08-03 | Leschly Nick (President and CEO) | Sale | 444 | 60.65 | 26,928 |
| 2020-08-03 | Cole Jason (Chief Operating and) | Sale | 37 | 60.65 | 2,244 |
| 2020-08-03 | Gregory Philip D (Chief Scientific Officer) | Sale | 59 | 60.65 | 3,578 |
| 2020-08-03 | Smith-farrell Joanne (Chief Business Officer) | Sale | 37 | 60.65 | 2,244 |
| 2020-07-20 | Wentworth Kory James (Principal Accounting Officer) | Sale | 596 | 66.38 | 39,562 |
| 2020-07-02 | Finger Alison Cecily (Chief Commercial Officer) | Sale | 36 | 61.57 | 2,216 |
| 2020-07-02 | Davidson David (Chief Medical Officer) | Sale | 42 | 61.57 | 2,586 |
| 2020-07-02 | Cole Jason (Chief Operating and) | Sale | 38 | 61.57 | 2,339 |
| 2020-07-02 | Gregory Philip D (Chief Scientific Officer) | Sale | 59 | 61.57 | 3,632 |
| 2020-06-04 | Wentworth Kory James (Principal Accounting Officer) | Sale | 154 | 65.28 | 10,053 |
| 2020-06-04 | Smith-farrell Joanne (Chief Business Officer) | Sale | 170 | 65.28 | 11,098 |
| 2020-06-02 | Finger Alison Cecily (Chief Commercial Officer) | Sale | 35 | 63.80 | 2,233 |
| 2020-06-02 | Davidson David (Chief Medical Officer) | Sale | 42 | 63.80 | 2,679 |
| 2020-06-02 | Leschly Nick (President and CEO) | Sale | 444 | 63.80 | 28,328 |
| 2020-06-02 | Cole Jason (Chief Operating and) | Sale | 38 | 63.80 | 2,424 |
| 2020-06-02 | Gregory Philip D (Chief Scientific Officer) | Sale | 59 | 63.80 | 3,764 |
| 2020-06-02 | Smith-farrell Joanne (Chief Business Officer) | Sale | 37 | 63.80 | 2,360 |
| 2020-05-04 | Smith-farrell Joanne (Chief Business Officer) | Sale | 232 | 50.75 | 11,774 |
| 2020-04-06 | Smith-farrell Joanne (Chief Business Officer) | Sale | 583 | 43.73 | 25,494 |
| 2020-02-13 | Baird William D Iii (Chief Financial Officer) | Sale | 1,254 | 90.60 | 113,612 |
| 2020-01-10 | Gregory Philip D (Chief Scientific Officer) | Sale | 600 | 94.03 | 56,415 |
| 2020-01-10 | Gregory Philip D (Chief Scientific Officer) | Option Ex | 600 | 50.51 | 30,306 |
| 2020-01-07 | Finger Alison Cecily (Chief Commercial Officer) | Sale | 1,049 | 89.97 | 94,379 |
| 2020-01-07 | Wentworth Kory James (Principal Accounting Officer) | Sale | 223 | 89.97 | 20,063 |
| 2020-01-07 | Davidson David (Chief Medical Officer) | Sale | 3,297 | 89.97 | 296,634 |
| 2020-01-07 | Leschly Nick (President and CEO) | Sale | 10,163 | 89.97 | 914,375 |
| 2020-01-07 | Cole Jason (Chief Operating and) | Sale | 1,957 | 89.97 | 176,073 |
| 2020-01-07 | Gregory Philip D (Chief Scientific Officer) | Sale | 4,134 | 89.97 | 371,940 |
| 2020-01-07 | Smith-farrell Joanne (Chief Business Officer) | Sale | 408 | 89.97 | 36,708 |
| 2020-01-06 | Gregory Philip D (Chief Scientific Officer) | Sale | 250 | 86.66 | 21,665 |
| 2020-01-03 | Finger Alison Cecily (Chief Commercial Officer) | Sale | 517 | 84.96 | 43,924 |
| 2019-12-19 | Wentworth Kory James (Principal Accounting Officer) | Sale | 397 | 92.59 | 36,758 |
| 2019-12-17 | Gregory Philip D (Chief Scientific Officer) | Sale | 1,800 | 94.31 | 169,749 |
| 2019-12-17 | Gregory Philip D (Chief Scientific Officer) | Option Ex | 1,800 | 50.51 | 90,918 |
| 2019-12-05 | Gregory Philip D (Chief Scientific Officer) | Sale | 250 | 80.57 | 20,142 |
| 2019-10-07 | Gregory Philip D (Chief Scientific Officer) | Sale | 250 | 89.07 | 22,266 |
| 2019-09-10 | Davidson David (Chief Medical Officer) | Sale | 2,060 | 100.16 | 206,323 |
| 2019-09-10 | Davidson David (Chief Medical Officer) | Option Ex | 2,060 | 50.51 | 104,050 |
| 2019-09-09 | Davidson David (Chief Medical Officer) | Sale | 3,000 | 100.11 | 300,339 |
| 2019-09-09 | Davidson David (Chief Medical Officer) | Option Ex | 3,000 | 50.51 | 151,530 |
| 2019-09-05 | Gregory Philip D (Chief Scientific Officer) | Sale | 850 | 101.20 | 86,018 |
Insider trading activities including stock purchases, stock sales, and option exercises
of BLUE listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Bluebird Bio, Inc. (symbol BLUE,
CIK number 1293971) see
the Securities and Exchange Commission (SEC) website.